Evogene (EVGN) Accumulated Expenses (2016 - 2025)

Evogene (EVGN) has disclosed Accumulated Expenses for 9 consecutive years, with $861000.0 as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses fell 53.93% to $861000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $861000.0 through Dec 2025, down 53.93% year-over-year, with the annual reading at $861000.0 for FY2025, 53.93% down from the prior year.
  • Accumulated Expenses hit $861000.0 in Q4 2025 for Evogene, down from $1.9 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $2.7 million in Q4 2021 to a low of $861000.0 in Q4 2025.
  • Historically, Accumulated Expenses has averaged $2.0 million across 5 years, with a median of $2.0 million in 2022.
  • Biggest five-year swings in Accumulated Expenses: grew 27.68% in 2023 and later tumbled 53.93% in 2025.
  • Year by year, Accumulated Expenses stood at $2.7 million in 2021, then dropped by 25.36% to $2.0 million in 2022, then rose by 27.68% to $2.5 million in 2023, then dropped by 26.33% to $1.9 million in 2024, then crashed by 53.93% to $861000.0 in 2025.
  • Business Quant data shows Accumulated Expenses for EVGN at $861000.0 in Q4 2025, $1.9 million in Q4 2024, and $2.5 million in Q4 2023.